Published in Molecular Therapy – Nucleic Acids, this study shows how targeted RNA modulation can restore protein function—paving the way for therapeutic strategies to treat genetic diseases caused by nonsense mutations and splicing defects.

“This is the first patch designed to capture disease-specific exosomes from fluid under the skin. The potential applications are huge,” – Dr. Sunitha Nagrath

“The next-generation designs aim to handle the more challenging in vivo conditions, such as high fluid shear and irregular tissue architectures,” – Dr. Sharon Glotzer

“It’s a $40 device to solve a $40,000 problem, You can wear it comfortably, it requires no special training, and it could be used anywhere, from hospitals to ambulances to battlefield care,” – Dr. Scott VanEpps

“Dr. Willsey is a remarkable addition… closely aligned with Paradromics’ mission to create life‑improving neurotechnology for people with neurological disorders,” — Matt Angle, PhD, Paradromics CEO

“By uncovering how the physical structure of materials guides immune responses and infection outcomes, we hope to establish design rules for infection-resistant biomaterials,” – Dr. Jouha Min

“The fluorescent material reached record-breaking brightness and efficiency with 98% quantum efficiency in the solid state and 94% in solution” – Dr. Jinsang Kim

“Our research fundamentally changes the armamentarium of our people’s fight against these diseases. We create nanoparticles that mimic proteins that can avoid defense mechanisms of cancerous cells,”

– Dr. Nicholas Kotov

Researchers have developed the ExoPatch, a minimally invasive microneedle patch that captures melanoma-specific exosomes directly from the skin for rapid, point-of-care diagnosis. In preclinical tests, it significantly outperformed traditional methods in distinguishing melanoma from healthy tissue, offering a promising tool for early detection and routine monitoring.